Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;17(22):2847-2855.
doi: 10.2217/fon-2021-0176. Epub 2021 May 12.

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma

Josep Tabernero  1 , Yung-Jue Bang  2 , Eric Van Cutsem  3 , Charles S Fuchs  4 , Yelena Yuriy Janjigian  5 , Pooja Bhagia  6 , Kan Li  6 , David Adelberg  6 , Shu Kui Qin  7
Affiliations

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma

Josep Tabernero et al. Future Oncol. 2021 Aug.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Future Oncol. 2023 Jun;19(17):1229. doi: 10.2217/fon-2021-0176c1. Epub 2023 Jun 9. Future Oncol. 2023. PMID: 37293712 Free PMC article. No abstract available.

Abstract

Current guidelines recommend two-drug cytotoxic chemotherapy with a fluoropyrimidine (fluorouracil or capecitabine) and a platinum-based agent (oxaliplatin or cisplatin) as first-line treatment for advanced gastric cancer. Pembrolizumab monotherapy has demonstrated durable antitumor activity in patients with advanced programmed death ligand 1-positive (combined positive score ≥1) gastric/gastroesophageal junction adenocarcinoma. Accumulating evidence indicates that combining pembrolizumab with standard-of-care chemotherapy for the treatment of advanced or metastatic cancer improves clinical outcomes. We describe the rationale for and the design of the randomized, double-blind, placebo-controlled, Phase III KEYNOTE-859 study, which is investigating pembrolizumab in combination with chemotherapy as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma. The planned sample size is 1542 patients, and the primary end point is overall survival. Clinical trial registration: NCT03675737 (ClinicalTrials.gov).

Keywords: HER2-negative; adenocarcinoma; chemotherapy; first-line therapy; gastric cancer; gastroesophageal junction cancer; immunotherapy; pembrolizumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. KEYNOTE-859 study design.
CAPOX: Capecitabine plus oxaliplatin; CPS: Combined positive score; ECOG PS: Eastern Cooperative Oncology Group performance status; FP: 5-Fluorouracil plus cisplatin; GEJ: Gastroesophageal junction; iv.: Intravenously; Q3W: Every 3 weeks.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). - PubMed
    1. Ferlay J, Colombet M, Soerjomataram I et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144(8), 1941–1953 (2019). - PubMed
    1. Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 64(12), 1881–1888 (2015). - PubMed
    1. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202–209 (2014). - PMC - PubMed
    1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): gastric cancer (version 4.2020). (2020). https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.o... - PubMed

Publication types

MeSH terms

Supplementary concepts

Associated data